Track market-moving stories before they get noisy

Proven Industry Leader to Guide Company’s Next Chapter of Growth and Value Creation

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) today announced that Jason Weidman has been appointed President and Chief Executive Officer, effective June 8, 2026. He will succeed Stuart Randle, who has been serving as Interim President and CEO since January 2026 and will continue as a member of Teleflex’s Board of Directors. Mr. Weidman is expected to join the Teleflex Board when he assumes his role as President and CEO.

Mr. Weidman is a proven medical technology leader with over 25 years of industry experience and a strong track record of building and scaling businesses globally. He joins Teleflex from Medtronic plc, where he held a number of senior leadership roles over nearly two decades, most recently serving as SVP and President, Coronary & Renal Denervation, and SVP and President, Aortic, Peripheral and Venous. In these positions, he oversaw significant growth and global expansion of multi-billion dollar revenue operating units, including the successful launch of key innovations and acquisitions.

“We’re thrilled to welcome Jason to Teleflex. Following the completion of the divestitures, Teleflex will be a fundamentally transformed company, with a portfolio focused on our core interventional, critical care and high acuity hospital markets,” said Dr. Stephen Klasko, Teleflex’s Chairman of the Board. “Jason’s medical technology expertise is closely aligned with our focused product portfolio, and his track record of driving growth, advancing product innovations and expanding global markets make him an ideal candidate to lead Teleflex’s go-forward strategy. With attractive, high-growth end markets, what will be a significantly enhanced capital structure from our intended $1 billion share buyback and $800 million debt paydown following the close of the sale transactions and an experienced and driven leadership team, we believe Teleflex will be an incredibly compelling growth story.”

“It’s an honor for me to join Teleflex at such an important inflection point and to help lead the Company into its next phase of growth,” said Mr. Weidman. “Having spent my entire career in the medical technology industry, I see a clear opportunity for Teleflex to build on its strong foundation and commitment to innovation, further shaping the future of healthcare while advancing our purpose of improving the health and quality of people’s lives.”

Dr. Klasko added, “I also want to thank Stuart for his leadership over the past four months. The Board and I are grateful for his contributions and value his continued insights and guidance as a member of our Board.”

About Jason Weidman

Mr. Weidman brings over 25 years of experience in the medical device industry. He held key leadership roles at Medtronic from 2006 – 2026, including his most recent roles of SVP and President, Coronary & Renal Denervation and SVP and President, Aortic, Peripheral and Venous, where he spearheaded strategic product innovations and market development initiatives in coronary and peripheral vascular markets. Prior to Medtronic, Mr. Weidman held roles at Thoratec Corporation.

Mr. Weidman received an MBA in Health Care Management from the Wharton School at the University of Pennsylvania, an MS in Mechanical Engineering with a concentration in Biomechanics from Stanford University and a BSE in Mechanical Engineering from the University of Michigan.

About Teleflex Incorporated

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2026.

First quarter 2026 continuing operations financial summary1

Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS from continuing operations of $1.39, compared to $1.44 in the prior year period 2026 continuing operations guidance summary1

Maintaining GAAP revenue growth guidance range of 14.40% to 15.40% Maintaining pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%2 Maintaining GAAP EPS from continuing operations guidance range of $2.90 to $3.20 Maintaining Adjusted diluted EPS from continuing operations guidance range to $6.25 to $6.55 Includes full year impact of stranded costs estimated to be $90 million Excludes expected benefits from transition services (“TS”) and manufacturing services (“MS”) agreements that come into effect upon closing of Strategic Divestitures, which we anticipate will fully offset stranded costs on an annualized basis Excludes impact of repurchases under previously announced $1 billion share repurchase program and expected debt paydown of ~$800 million primarily funded by closing of Strategic Divestitures "Our first-quarter performance reflects disciplined execution and meaningful progress against our transformation plan," said Stuart Randle, Teleflex's Interim President and Chief Executive Officer. "We delivered a strong start to the year, with 5.1% pro forma adjusted constant currency revenue growth year-over-year, and we continue to expect our two strategic divestitures to close in the second half of 2026. We remain committed to using the majority of the net proceeds from the sales transactions to return capital to shareholders through our $1 billion share repurchase authorization, while also reducing debt by $800 million to enhance financial flexibility and support future growth. These actions are advancing our strategy to optimize our portfolio, strengthen Teleflex's position as a focused medical technologies leader and drive long-term value creation."

Mr. Randle continued, “We recently announced the appointment of Jason Weidman as President and Chief Executive Officer, effective June 8, 2026. His deep medical technology expertise and proven track record of driving growth and innovation make him well suited to lead Teleflex into its next chapter and capitalize on the opportunities ahead. Additionally, consistent with our commitment to strong governance and creating shareholder value, we announced several actions in April, including the nomination of Michael J. Tokich to our Board of Directors, the initiation of opportunistic open-market share repurchases in the second quarter and our intent to establish a new Growth and Operating Committee of the Board.”

(1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the “Strategic Divestitures".

(2) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment and (b) the impact of foreign exchange.

NET REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding net revenues in each of the Company's global product categories for the three months ended March 31, 2026 and the comparable prior year period on both a GAAP and pro forma adjusted constant currency basis.

Three Months Ended

March 31, 2026

March 30, 2025

% Increase

/

(Decrease)

Reported

revenue

Adjustment

Pro Forma

Adjusted

Revenue

Reported

revenue

Adjustment

Pro Forma

Adjusted

Revenue

Reported

Revenue

Growth

Currency

Impact

Adjustment

impact

Pro Forma

Adjusted

Constant

Currency

Revenue

Growth

Vascular Access

$236.8

$—

$236.8

$219.1

$—

$219.1

8.1%

3.3%

—%

4.8%

Interventional1

204.7

—

204.7

100.2

92.6

192.8

104.4%

3.1%

98.3%

3.0%

Surgical2

106.8

—

106.8

95.0

(0.5)

94.5

12.4%

3.1%

(0.6)%

9.9%

Consolidated1

$548.3

$—

$548.3

$414.3

$92.1

$506.4

32.3%

3.2%

24.0%

5.1%

OTHER CONTINUING OPERATIONS FINANCIAL HIGHLIGHTS

Depreciation expense, amortization of intangible assets and deferred financing charges for the three months ended March 31, 2026 totaled $55.2 million compared to $39.5 million for the prior year period. Total cash, cash equivalents and restricted cash equivalents at March 31, 2026 were $329.6 million compared to $402.7 million at December 31, 2025. Net accounts receivable at March 31, 2026 were $365.5 million compared to $345.6 million at December 31, 2025. Inventories at March 31, 2026 were $380.9 million compared to $404.4 million at December 31, 2025. 2026 CONTINUING OPERATIONS OUTLOOK

On a GAAP basis, the Company continues to expect full year 2026 revenue growth from continuing operations of 14.40% to 15.40%, including our estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations. On a pro forma adjusted constant currency basis, the Company is maintaining full year 2026 revenue growth from continuing operations of 4.50% to 5.50%.

The Company maintained its full year 2026 GAAP diluted earnings per share from continuing operations outlook range of $2.90 to $3.20. The Company continues to expect full year 2026 adjusted diluted earnings per share from continuing operations of $6.25 to $6.55.

Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation

2025

2026 Guidance

Low

High

GAAP revenue

$1,992.7

$2,280

$2,300

Vascular Intervention pro forma adjustment

$199.0

—

—

Discontinued product adjustment

$(14.3)

—

—

Italian payback measure adjustment

$(9.0)

—

—

Pro forma adjusted revenue

$2,168.4

$2,280

$2,300

Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From Continuing Operations Reconciliation

Low

High

Forecasted 2026 GAAP revenue growth

14.4%

15.4%

Vascular Intervention pro forma adjustment

10.0%

10.0%

Discontinued product adjustment

(0.7)%

(0.7)%

Italian payback measure adjustment

(0.5)%

(0.5)%

Base year adjustment (GAAP versus pro forma adjusted)

0.4%

0.4%

Estimated impact of foreign currency exchange rate fluctuations

0.7%

0.7%

Forecasted 2026 pro forma adjusted constant currency revenue growth

4.5%

5.5%

Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation

Low

High

Forecasted GAAP diluted earnings per share from continuing operations

$2.90

$3.20

Restructuring and optimization items, net of tax

$0.90

$0.90

Acquisition, integration and divestiture related items, net of tax

$0.61

$0.61

Other items, net of tax

$(0.65)

$(0.65)

ERP implementation, net of tax

$0.30

$0.30

MDR, net of tax

$0.02

$0.02

Intangible amortization expense, net of tax

$2.17

$2.17

Forecasted adjusted diluted earnings per share from continuing operations, net of tax

$6.25

$6.55

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

A webcast of Teleflex's first quarter 2026 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on May 7, 2026.

An audio replay of the investor call will be available beginning at 11:00 am ET on May 7, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The confirmation code is 69028.

ADDITIONAL NOTES

References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.

Pro forma adjusted revenue and pro forma adjusted constant currency revenue growth give effect to, among other things, our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. The pro forma information is presented for informational purposes only and is not necessarily indicative of the historical results that would have occurred under our ownership and management, nor the results that may be obtained in the future.

Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES

We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP”. In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: pro forma adjusted revenues, pro form adjusted constant currency revenue growth, and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

Pro forma adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to (i) exclude products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025.

Pro forma adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges.

Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed.

Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis. In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis. The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance.

Other - These are discrete items that occur sporadically and can affect period-to-period comparisons.

European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.

Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

PRO FORMA ADJUSTED REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding pro forma adjusted revenues in each of the Company's global product categories in continuing operations for the three months ended March 31, 2026 and the comparable prior year period.

Q1 2026

Q1 2025

Vascular

236.8

219.1

Interventional

204.7

100.2

Surgical

106.8

95.0

GAAP revenue

548.3

414.3

Interventional - Vascular Intervention

—

95.2

Interventional - Discontinued Products

—

(2.6)

Surgical - Discontinued Products

—

(0.5)

Pro forma adjusted revenue

$548.3

$506.4

Vascular

236.8

219.1

Interventional

204.7

192.8

Surgical

106.8

94.5

Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

Three Months Ended March 31, 2026

Revenue

Gross

margin

SG&A (1)

R&D (1)

Operating

margin (2)

(Loss) Income

before income

taxes

Income tax

expense

Effective

income tax

rate

Diluted (loss)

earnings per

share from

continuing

operations

GAAP Basis - Continuing Operations

$548.3

56.1%

41.2%

8.1%

3.7%

$(3.8)

$1.0

(26.4)%

$(0.11)

Adjustments

Restructuring and optimization charges (A)

—

0.6

(1.4)

—

5.0

28.0

4.4

0.54

Acquisition, integration and divestiture related items (B)

—

1.4

(1.0)

—

2.4

13.0

3.1

0.22

ERP implementation

—

—

(0.7)

—

0.7

3.9

0.7

0.07

MDR

—

—

—

(0.1)

0.1

0.4

—

0.01

Intangible amortization expense

—

3.3

(2.9)

—

6.2

33.9

4.6

0.66

Adjustments total

—

5.3

(6.0)

(0.1)

14.4

79.2

12.8

1.50

Adjusted basis

$548.3

61.4%

35.2%

8.0%

18.1%

$75.4

$13.8

18.3%

$1.39

Three Months Ended March 30, 2025

Revenue

Gross

margin

SG&A (1)

R&D (1)

Operating

margin (2)

Income before

income taxes

Income tax

expense

Effective

income tax

rate

Diluted

earnings per

share from

continuing

operations

GAAP Basis - Continuing Operations

$414.3

61.7%

36.9%

6.1%

18.3%

$58.8

$6.4

10.9%

$1.14

Adjustments

Restructuring and optimization charges (A)

—

1.1

—

—

1.5

6.0

1.0

0.11

Acquisition, integration and divestiture related items (B)

—

—

4.4

—

(4.4)

(18.1)

0.8

(0.42)

ERP implementation

—

—

(1.4)

—

1.4

5.9

1.0

0.11

MDR

—

—

—

(0.2)

0.2

0.7

—

0.02

Intangible amortization expense

—

3.3

(2.9)

—

6.2

25.6

3.1

0.49

Tax adjustments

—

—

—

—

—

—

0.7

(0.01)

Adjustments total

—

4.4

0.1

(0.2)

4.9

20.1

6.6

0.30

Adjusted basis

$414.3

66.1%

37.0%

5.9%

23.2%

$78.9

$13.0

16.4%

$1.44

Notes:

(1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.

(2) Operating margin defined as Income from continuing operations before interest and taxes as a percentage of as reported and adjusted revenues.

Totals may not sum due to rounding.

Tickmarks to Reconciliation Tables

ABOUT TELEFLEX INCORPORATED

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, forecasted 2026 GAAP, pro forma adjusted and pro forma adjusted constant currency revenue and revenue growth and GAAP and adjusted diluted earnings per share; our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2026 financial results; statements about the pending Strategic Divestitures, the expected timetable for completing the Strategic Divestitures and the future financial and operating performance of the company following completion of the Strategic Divestitures; statements regarding our intended use of the net proceeds from the Strategic Divestitures; and statements regarding our ability to drive durable performance and long-term value for shareholders. Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; the possibility that the Strategic Divestitures do not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the Strategic Divestitures; customer and shareholder reaction to the Strategic Divestitures; disruption from the Strategic Divestitures that may make it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(Unaudited)

Three Months Ended

March 31, 2026

March 30, 2025

(Dollars and shares in thousands, except per share)

Net revenues

$

548,262

$

414,258

Cost of goods sold

240,836

158,827

Gross profit

307,426

255,431

Selling, general and administrative expenses

226,012

152,914

Research and development expenses

44,386

25,295

Restructuring charges, separation costs and impairment charges

16,845

1,422

Income from continuing operations before interest and taxes

20,183

75,800

Interest expense

25,718

18,537

Interest income

(1,708

)

(1,488

)

(Loss) income from continuing operations before taxes

(3,827

)

58,751

Taxes on income from continuing operations

1,011

6,417

(Loss) income from continuing operations

(4,838

)

52,334

Operating (loss) income from discontinued operations

(2,643

)

50,060

Taxes on operating income from discontinued operations

673

7,392

(Loss) income from discontinued operations

(3,316

)

42,668

Net (loss) income

$

(8,154

)

$

95,002

Earnings per share:

Basic:

(Loss) Income from continuing operations

$

(0.11

)

$

1.14

(Loss) Income from discontinued operations

(0.07

)

0.94

Net (loss) income

$

(0.18

)

$

2.08

Diluted:

(Loss) Income from continuing operations

$

(0.11

)

$

1.14

(Loss) Income from discontinued operations

(0.07

)

0.93

Net (loss) income

$

(0.18

)

$

2.07

Weighted average common shares outstanding

Basic

44,257

45,782

Diluted

44,257

45,926

TELEFLEX INCORPORATED

CONSOLIDATED BALANCE SHEETS

(Unaudited)

March 31, 2026

December 31, 2025

(Dollars in thousands)

ASSETS

Current assets

Cash and cash equivalents

$

309,411

$

378,564

Accounts receivable, net

365,526

345,583

Inventories

380,861

404,395

Prepaid expenses and other current assets

149,808

150,678

Prepaid taxes

16,793

19,566

Current assets of discontinued operations

637,271

639,552

Total current assets

1,859,670

1,938,338

Property, plant and equipment, net

476,955

498,281

Operating lease assets

84,912

91,817

Goodwill

2,297,447

2,305,050

Intangibles assets, net

1,485,885

1,524,150

Deferred tax assets

12,206

12,593

Other assets

113,557

112,984

Non-current assets of discontinued operations

452,370

464,026

Total assets

6,783,002

6,947,239

LIABILITIES AND EQUITY

Current liabilities

Current borrowings

$

103,125

$

100,000

Accounts payable

143,627

130,201

Accrued expenses

118,423

117,350

Payroll and benefit-related liabilities

103,345

124,769

Accrued interest

16,478

5,404

Income taxes payable

11,824

18,787

Other current liabilities

103,929

137,195

Current liabilities of discontinued operations

127,298

128,320

Total current liabilities

728,049

762,026

Long-term borrowings

2,514,268

2,541,449

Deferred tax liabilities

169,429

183,749

Noncurrent liability for uncertain tax positions

3,831

3,536

Noncurrent operating lease liabilities

68,320

84,210

Other liabilities

162,507

194,532

Non-current liabilities of discontinued operations

52,162

52,969

Total liabilities

3,698,566

3,822,471

Commitments and contingencies

Total shareholders' equity

3,084,436

3,124,768

Total liabilities and shareholders' equity

$

6,783,002

$

6,947,239

  TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three Months Ended

March 31, 2026

March 30, 2025

(Dollars in thousands)

Cash flows from operating activities of continuing operations:

Net (loss) income

$

(8,154

)

$

95,002

Adjustments to reconcile net income to net cash provided by operating activities:

(Income) loss from discontinued operations

3,316

(42,668

)

Depreciation expense

19,853

13,037

Intangible asset amortization expense

33,890

25,583

Deferred financing costs and debt discount amortization expense

1,481

851

Changes in contingent consideration

(2,632

)

(1,795

)

Stock-based compensation

6,742

6,630

Gain on non-designated foreign currency forward contracts

—

(23,268

)

Deferred income taxes, net

(12,710

)

(108

)

Interest benefit on swaps designated as net investment hedges

(8,305

)

(4,239

)

Other

3,558

762

Changes in assets and liabilities, net of effects of acquisitions and disposals:

Accounts receivable

(25,005

)

(10,939

)

Inventories

16,473

(3,474

)

Prepaid expenses and other assets

3,432

(12,724

)

Accounts payable, accrued expenses and other liabilities

8,197

(17,488

)

Income taxes receivable and payable, net

6,526

2,562

Net cash provided by operating activities from continuing operations

46,662

27,724

Cash flows from investing activities of continuing operations:

Expenditures for property, plant and equipment

(18,791

)

(24,132

)

Payments for businesses and intangibles acquired, net of cash acquired

—

(90

)

Insurance settlement proceeds

—

6,307

Net payments on swaps designated as net investment hedges

(53,494

)

—

Purchase of investments

(2,500

)

(5,000

)

Net cash used in investing activities from continuing operations

(74,785

)

(22,915

)

Cash flows from financing activities of continuing operations:

Proceeds from new borrowings

—

300,000

Reduction in borrowings

(25,250

)

(49,125

)

Repurchase of common stock

—

(300,000

)

Net (payments) proceeds from share based compensation plans and related tax impacts

(4,627

)

7,348

Payments for contingent consideration

(58

)

(56

)

Dividends paid

(15,050

)

(15,191

)

Debt extinguishment, issuance and amendment fees

—

(2,500

)

Net cash used in financing activities from continuing operations

(44,985

)

(59,524

)

Cash flows from discontinued operations:

Net cash provided by operating activities

2,362

45,370

Net cash used in investing activities

(9,214

)

(5,879

)

Net cash used in discontinued operations

(6,852

)

39,491

Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents

(4,890

)

5,052

Net increase in cash, cash equivalents and restricted cash equivalents

(84,850

)

(10,172

)

Cash, cash equivalents and restricted cash equivalents at the beginning of the period

453,848

327,650

Less: Cash, cash equivalents and restricted cash of discontinued operations

(39,448

)

(35,397

)

Cash, cash equivalents and restricted cash equivalents at the end of the period

$

329,550

$

282,081

For the quarter ended March 2026, Teleflex (TFX - Free Report) reported revenue of $548.26 million, down 21.8% over the same period last year. EPS came in at $1.39, compared to $2.91 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $533.74 million, representing a surprise of +2.72%. The company delivered an EPS surprise of +14.75%, with the consensus EPS estimate being $1.21.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Surgical: $106.8 million compared to the $102.19 million average estimate based on 11 analysts. The reported number represents a change of +1% year over year.Revenues- Interventional: $204.7 million compared to the $210.39 million average estimate based on eight analysts.Revenues- Vascular: $236.8 million compared to the $223.03 million average estimate based on eight analysts.View all Key Company Metrics for Teleflex here>>>

Shares of Teleflex have returned +3.5% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Key Takeaways Teleflex Q1 revenues rose 32.3% to $548.3M, topping estimates on strong segment growth.TFX gross margin fell 559 bps to 56.1% as the cost of goods sold jumped 51.6% year over year.Teleflex reaffirmed 2026 revenue and adjusted EPS guidance despite margin pressure. Teleflex Inc. (TFX - Free Report) posted first-quarter 2026 adjusted earnings per share (EPS) from continuing operations of $1.39, down 3.5% from the year-ago quarter’s figure. However, the metric topped the Zacks Consensus Estimate by 14.75%.

GAAP loss per share was 11 cents compared to EPS of $1.14 in the prior-year period.

TFX’s RevenuesFirst-quarter revenues from continuing operations were $548.26 million, up 32.3% year over year and surpassed the Zacks Consensus Estimate by 2.72%.

On a pro forma adjusted constant currency basis — which includes prior-year revenues from the acquired Vascular Intervention business, and excludes foreign exchange and revenues from products discontinued after the 2025 strategic realignment — revenues rose 5.1% in the quarter.

Since the announcement on May 7, shares of the company have fallen 2% to close the session at $131.56 yesterday.

Segmental Analysis of TFX’s Q1 RevenuesThe Vascular segment recorded pro forma adjusted revenues of $236.8 million, up 8.1% on a reported basis and 4.8% on a pro forma adjusted constant currency basis. Growth was mainly driven by hemostatic products in the central venous and other access portfolio.

The Interventional business registered pro forma adjusted revenues of $204.7 million, up 104.4% on a reported basis and 3% on a pro forma adjusted constant currency basis. Performance was led by the intraosseous, right heart catheters and complex catheters.

The Surgical segment recorded pro forma adjusted revenues of $106.8 million, up 12.4% on a reported basis and up 9.9% on a pro forma adjusted constant currency basis. Growth was led by the strong performance in the ligation clip and some timing of orders in the instrument portfolio.

TFX’s Q1 Margin PerformanceThe gross profit was $307.4 million, up 20.4% year over year. The gross margin contracted 559 basis points (bps) to 56.1% due to a 51.6% rise in the cost of goods sold.

Overall, the adjusted operating profit was $37 million, down 52.1% year over year. The adjusted operating margin contracted 1189 bps to 6.8%.

TFX’s Liquidity PositionTeleflex exited the first quarter of 2026 with cash and cash equivalents of $309.4 million compared with $378.6 million at the end of 2025.

Net cash flow provided by operating activities from continuing operations was $46.7 million compared with $27.7 million in the year-ago period.

Teleflex’s 2026 GuidanceOn a GAAP basis, the company continues to expect full-year 2026 revenue growth from continuing operations of 14.4% to 15.4%. Pro forma adjusted constant currency revenue growth for 2026 is also unchanged at 4.50% to 5.50%.

The Zacks Consensus Estimate for total revenues is pegged at $2.29 billion, indicating a 22.9% decline.

Adjusted EPS from continuing operations is projected in the range of $6.25-$6.55, also unchanged from the previous forecast. The Zacks Consensus Estimate for the metric is pegged at $8.41.

Our TakeTeleflex delivered better-than-expected earnings and revenues in the first quarter of 2026. The company demonstrated strong execution and also, to some extent, benefited from the timing of orders in its surgical instrument portfolio. Within Interventional, Teleflex continues to integrate the Vascular Intervention business, which closed early in the third quarter of 2025. The company is also making progress on its strategic priorities, which include driving durable performance and building a clear financial profile through improved margins, lower interest expense and stronger adjusted EPS over time.

Meanwhile, the strategic divestitures of the acute care, interventional urology and OEM businesses are expected to close in the second half of 2026.

TFX’s Zacks Rank and Key PicksTeleflex currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Intuitive Surgical (ISRG - Free Report) and Labcorp Holdings (LH - Free Report) .

BrightSpring Health Services, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of 36 cents, which surpassed the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

BTSG has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 14.61%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has an earnings yield of 2.1% compared to the industry’s negative 0.9% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.

Labcorp, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 3.8%. Revenues of $3.54 billion outperformed the Zacks Consensus Estimate by 1%.

LH has an earnings yield of 6.9% compared with the industry’s 4.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 3.31%.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical needs while ensuring patients can recover and maintain their quality of life long after treatment.

In parallel with Teleflex’s long-term strategy to significantly streamline the Teleflex business and narrow focus to the critical care and high-acuity hospital end-markets, the company’s Interventional Urology business unit continues to drive clinical value as it prepares for its divestiture in the second half of 2026.

Data presented at the 2026 American Urological Association (AUA) Annual Meeting in Washington, DC. May 15 – 18 and the European Society for Radiotherapy & Oncology (ESTRO) Congress held in Stockholm May 15 – 19 highlight early patient experience following BPH treatment1 with the UroLift™ System and sustained reductions in radiation-associated toxicity for prostate cancer patients who received Barrigel™ rectal spacer.2

CLEAR RCT: First Head-to-Head Comparison of Minimally Invasive Surgical Therapies (MISTs) Demonstrates Favorable Early Patient Experience with the UroLift™ System*

At AUA 2026, Dr. Bilal Chughtai**, a urologist with Northwell Health, Garden City, N.Y., presented 12-month findings from the CLEAR (Comparing UroLift™ Experience Against Rezūm™) randomized controlled trial, the first prospective, multicenter, head-to-head RCT comparing MISTs for BPH.1

The study evaluated key endpoints including catheter independence, symptom improvement, patient experience, and sexual function.1

Key study endpoints of the study:

Catheter independence from day three through day seven was significantly better among UroLift™ System patients compared to Rezūm™ patients, with 3 percent requiring catheter versus 20 percent (p=.02) respectively1 Early patient experience was better for the UroLift™ System patients compared to Rezūm™ patients1 UroLift™ System and Rezūm™ subjects had similar durability through 12 months1 Patients’ sexual function† was preserved through 12 months with the UroLift™ System1 “What stands out in our CLEAR RCT study is the consistency of the early patient experience advantages with the UroLift™ System, particularly catheter independence, rapid recovery, and preservation of sexual function, which are critical factors for both patients and physicians when selecting a treatment approach,” said Dr. Bilal Chughtai**, a urologist practicing in Syosset, N.Y.

Barrigel™ Rectal Spacer Three-Year Data Demonstrate Sustained Reduction in Radiation-Associated Toxicity*

At ESTRO 2026, new three-year outcomes presented by Dr. Martin King** highlighted the long-term safety and effectiveness of Barrigel™ rectal spacer.2

Key endpoints of the study:

Patients in the Barrigel™ rectal spacer arm of the study experienced a continued Grade 2+ toxicity benefit sustained through three years. Zero percent of the Barrigel™ rectal spacer patients experienced Grade 2+ toxicity versus 10 percent in the control arm2 Fewer patients with greater than one centimeter of apical spacing had a decline in bowel quality of life at 36 months versus control2 These results demonstrate a durable benefit for the Barrigel™ rectal spacer subjects sustained through three years, reinforcing the role of rectal spacing in protecting bowel function during and after radiation therapy.2

“The three-year data further validate the clinical value of Barrigel™ rectal spacer, demonstrating sustained and clinically meaningful reductions in gastrointestinal toxicity,” said Martin King**, MD, PhD, presenter and radiation oncologist with the Dana-Farber Brigham Cancer Center, Harvard Medical School Associate Professor of Radiation Oncology. “Reducing radiation treatment-related toxicity is essential for prostate cancer patients, and these findings support the continued adoption of rectal spacing as a standard component of care.” 2

“These data reflect our prostate health leadership and ongoing commitment to advancing evidence-based, patient-centered solutions across the urology care continuum,” said Travis Gay, President and General Manager, Interventional Urology, Teleflex. “From improving early recovery and preserving sexual function in BPH patients with the UroLift™ System to delivering durable protection against radiation-related rectal toxicity with Barrigel™ spacer, we are focused on technologies that meaningfully improve patients’ lives.”

About the UroLift™ System
The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,3 relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.4,5 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.†6-7 A study conducted over five years showed a low retreatment rate of about 2 to 3 percent per year, or a total of 13.6 percent over the course of the study, demonstrating UroLift™ System durability.8 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.9 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift™ System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.10 Learn more at www.UroLift.com.

UroLift System Important Safety Information
The UroLift™ System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 45 years or older with prostates ≤100 cc. Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence due to incompetent sphincter, and urethral conditions that prevent device insertion. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. Visit urolift.com.

About Barrigel™ Rectal Spacer
Barrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.11 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).12

Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.13,14

Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy11 and is cleared for rectal spacing in the United States, Australia, and Europe.15 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters.

Barrigel™ Rectal Spacer Important Safety Information
Barrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, the intent is to reduce the radiation dose delivered to the anterior rectum. It is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time.

It should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area.

Potential complications include but are not limited to: pain associated with the injection; needle penetration or injection of Barrigel rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. Contraindicated in prostate cancer patients with clinical stage T4 disease. Individual results may vary. Visit barrigel.com.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

About Interventional Urology
The Interventional Urology Business Unit is leading in prostate health by advancing clinical evidence, elevating education, and supporting physicians and patients. Our portfolio includes Barrigel™ rectal spacer for men seeking to reduce rectal side effects associated with prostate cancer radiation therapy, the UroLift™ System for men suffering from BPH symptoms, and Deflux™ injectable gel for children with grades II-V vesicoureteral reflux (VUR).

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Barrigel, Deflux, and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2026 Teleflex Incorporated. All rights reserved. APM1495A

*Studies sponsored by Teleflex.

**Drs. Chughtai and King are paid consultants of Teleflex

†No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study

References

Chughtai et al. J Urol 2026 King M, Chao M et al. Prospective Randomized Controlled Trial of Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results. Presented at: European Society for Radiotherapy and Oncology 2026 Annual Congress; May 2026; Stockholm, Sweden. Proffered Paper 3623. Shore, Can J Urol 2014 Rukstalis, Prostate Cancer Prostatic Dis 2018 UroLift™ System Instructions for Use AUA BPH Guidelines 2003, 2020 McVary, Urology 2019 Roehrborn, Can J Urol 2017 Roehrborn, J Urol 2013 Management estimate based on product sales as of June 2024. Data on file. Teleflex Interventional Urology. Mariados NF, Orio PF III, King M et al. JAMA Oncol (2023)*,** Barrigel Injectable Gel Instructions for Use (2022) Svatos M, Chell E, Low DA et al. Med Phys (2024)*,** Restylane® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021. Data on file Teleflex. 2025

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the “Notes”), subject to market and other conditions. The interest rate and other terms of the Notes will be determined at pricing.

The Notes will be guaranteed by each of Teleflex’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness.

Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the “2027 Notes”).

The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the United States only to investors who are reasonably believed to be “qualified institutional buyers,” as that term is defined in Rule 144A under the Securities Act, or to certain non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act. The Notes and the related guarantees have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not an offer to purchase or a solicitation of an offer to sell with respect to the 2027 Notes.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. Teleflex is the home of Arrow®, Barrigel®, Deknatel®, LMA®, Pilling®, QuikClot®, Rusch®, UroLift®, and Weck® - trusted brands united by a common sense of purpose.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements about the terms of and completion of the offering of the Notes, the anticipated use of the net proceeds from the offering and the redemption of the outstanding 2027 Notes. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K filed with the SEC on February 27, 2026 and our Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, which can be obtained on the SEC’s website at http://www.sec.gov. We undertake no obligation to publicly update or revise any forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the “Notes”) at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions.

The Notes will be guaranteed by each of Teleflex’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness.

Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the “2027 Notes”).

The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the United States only to investors who are reasonably believed to be “qualified institutional buyers,” as that term is defined in Rule 144A under the Securities Act, or to certain non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act. The Notes and the related guarantees have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not an offer to purchase or a solicitation of an offer to sell with respect to the 2027 Notes.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. Teleflex is the home of Arrow®, Barrigel®, Deknatel®, LMA®, Pilling®, QuikClot®, Rusch®, UroLift®, and Weck® - trusted brands united by a common sense of purpose.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements about the completion of the offering of the Notes, the anticipated use of the net proceeds from the offering and the redemption of the outstanding 2027 Notes. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K filed with the SEC on February 27, 2026 and our Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, which can be obtained on the SEC’s website at http://www.sec.gov. We undertake no obligation to publicly update or revise any forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

Brady Corporation (BRC) M&A Call Transcript

May 13, 2026 14:05 ET  | Source: Brady Corporation

MILWAUKEE, May 13, 2026 (GLOBE NEWSWIRE) -- Brady Corporation (NYSE: BRC), will announce its fiscal 2026 third quarter financial results on Monday, May 18, 2026.

A conference call will be held beginning at 10:30 a.m. Eastern Time (9:30 a.m. Central Time) Monday, May 18, 2026. Participants will be able to access the webcast and presentation here live and in replay.

This call is being webcast by Notified and can be accessed here.

About BRC
Brady Corporation is an international manufacturer and marketer of complete solutions that identify and protect people, products and places. Brady’s products help customers increase safety, security, productivity and performance and include high-performance labels, signs, safety devices, printing systems and software. Founded in 1914, the Company has a diverse customer base in electronics, telecommunications, manufacturing, electrical, construction, medical, aerospace and a variety of other industries. Brady is headquartered in Milwaukee, Wisconsin and as of July 31, 2025, employed approximately 6,400 people in its worldwide businesses. Brady’s fiscal 2025 sales were approximately $1.51 billion. Brady stock trades on the New York Stock Exchange under the symbol BRC. More information is available on the Internet at www.bradycorp.com.

For More Information:
Investor contact: Ann Thornton 414-438-6887
Media contact: Kate Venne 414-358-5176

Sales for the quarter increased 13.8 percent compared to the same quarter of the prior year. Organic sales increased 8.2 percent, acquisitions increased sales 2.1 percent and foreign currency translation increased sales 3.5 percent.Diluted EPS increased 11.0 percent to $1.21 in the third quarter of fiscal 2026 compared to $1.09 in the same quarter of the prior year. Adjusted Diluted EPS* increased 23.0 percent to $1.50 in the third quarter of fiscal 2026 compared to $1.22 in the same quarter of the prior year.Net cash provided by operating activities increased to $78.2 million in the third quarter of fiscal 2026 compared to $59.9 million in the third quarter of last year.GAAP earnings per diluted Class A Nonvoting Common share guidance for the year ending July 31, 2026 was adjusted from the previous range of $4.62 to $4.82 per share to $4.66 to $4.76 per share. Adjusted Diluted EPS* Guidance was raised for the full year ending July 31, 2026 from the previous range of $4.95 to $5.15 per share to the new range of $5.20 to $5.30 per share.Entered into a definitive purchase agreement on April 20, 2026, to acquire Honeywell’s Productivity Solutions and Services business, expected to close in the second half of calendar 2026, subject to regulatory approvals and customary closing conditions. MILWAUKEE, May 18, 2026 (GLOBE NEWSWIRE) -- Brady Corporation (NYSE: BRC) (“Brady” or “Company”), a world leader in identification solutions, today reported its financial results for its fiscal 2026 third quarter ended April 30, 2026.

Quarter Ended April 30, 2026 Financial Results:
Sales for the quarter ended April 30, 2026 increased 13.8 percent, which consisted of organic sales growth of 8.2 percent, growth of 2.1 percent from acquisitions and an increase of 3.5 percent from foreign currency translation. Sales for the quarter ended April 30, 2026 were $435.2 million compared to $382.6 million in the same quarter last year. By region, sales increased 14.4 percent in the Americas & Asia and sales increased 12.6 percent in Europe & Australia, which consisted of organic sales growth of 10.1 percent in the Americas & Asia and organic sales growth of 4.5 percent in Europe & Australia.

Income before income taxes increased 11.6 percent to $73.4 million in the quarter ended April 30, 2026, compared to $65.7 million in the same quarter last year. Adjusted Income Before Income Taxes* in the quarter ended April 30, 2026, which was adjusted for amortization expense of $5.3 million and acquisition-related costs of $13.5 million, was $92.1 million, an increase of 23.8 percent compared to the third quarter of last year. Adjusted Income Before Income Taxes* in the quarter ended April 30, 2025, which was adjusted for amortization expense and facility closure and other reorganization costs of $8.7 million, was $74.4 million.

Net income for the quarter ended April 30, 2026 was $57.8 million compared to $52.3 million in the same quarter last year. Adjusted Net Income* in the quarter ended April 30, 2026 was $71.9 million compared to $58.8 million in the same quarter last year. Earnings per diluted Class A Nonvoting Common Share was $1.21 compared to $1.09 in the same quarter last year. Adjusted Diluted EPS* in the quarter ended April 30, 2026 was $1.50 compared to $1.22 in the same quarter last year.

Nine-Month Period Ended April 30, 2026 Financial Results:
Sales for the nine-month period ended April 30, 2026 increased 9.7 percent, which consisted of organic sales growth of 4.3 percent, growth of 2.5 percent from acquisitions and an increase of 2.9 percent from foreign currency translation. Sales for the nine months ended April 30, 2026 were $1.22 billion compared to $1.12 billion in the same period last year. By region, sales increased 10.6 percent in the Americas & Asia and sales increased 8.0 percent in Europe & Australia, which consisted of organic sales growth of 6.0 percent in the Americas & Asia and organic sales growth of 0.9 percent in Europe & Australia.

Income before income taxes increased 15.4 percent to $203.8 million in the nine-month period ended April 30, 2026, compared to $176.6 million in the same period last year. Adjusted Income Before Income Taxes* in the nine-month period ended April 30, 2026, which was adjusted for amortization expense of $15.8 million and acquisition-related costs of $13.5 million, was $233.1 million, an increase of 13.5 percent compared to the same period last year. Adjusted Income Before Income Taxes* in the nine-month period ended April 30, 2025, which was adjusted for amortization expense, facility closure and other reorganization costs and acquisition-related charges of $28.8 million, was $205.4 million.

Net income in the nine-month period ended April 30, 2026 was $159.8 million compared to $139.4 million in the same period last year. Adjusted Net Income* in the nine-month period ended April 30, 2026 was $181.9 million compared to $161.1 million in the same period last year. Earnings per diluted Class A Nonvoting Common Share was $3.35 compared to $2.89 in the same period last year. Adjusted Diluted EPS* in the nine-month period ended April 30, 2026 was $3.81 compared to $3.34 in the same period last year.

Commentary:
“Our investment in research & development resulted in strong organic sales growth globally, along with a record quarter of adjusted earnings per share. New product launches over the last several years as well as data center construction drove our sales growth, which is an end market that is ideal for our high-performance identification solutions,” said Brady’s President and Chief Executive Officer, Russell R. Shaller. “Last month, we announced our agreement to acquire Honeywell’s Productivity Solutions and Services business, which we expect to close in the second half of calendar 2026. I’m incredibly excited to execute our plans for growth and expand our portfolio through PSS with high-quality mobility and scanning solutions, which are highly complementary to Brady’s portfolio of printers, software and specialty adhesive materials.”

“In addition to our new quarterly record adjusted earnings per share, we increased our cash flow from operating activities more than 30 percent to $78.2 million in the quarter, and we returned $16.7 million to our shareholders in the form of dividends and share buybacks,” said Brady’s Chief Financial Officer, Ann Thornton. “We were in a net cash position of $148.6 million as of April 30, 2026, which gives us the ability to continue to invest in organic growth and provides support for our acquisition of the Productivity Solutions and Services business, while returning funds to our shareholders to continue to drive long-term shareholder value.”

Fiscal 2026 Guidance:
The Company adjusted its GAAP earnings per diluted Class A Nonvoting Common Share guidance for the year ending July 31, 2026 from $4.62 to $4.82 per share, to $4.66 to $4.76 per share. The Company raised its Adjusted Diluted EPS* guidance for the year ending July 31, 2026 from $4.95 to $5.15 per share, to $5.20 to $5.30 per share.

The assumptions included in fiscal 2026 guidance include a full-year income tax rate of approximately 21 percent, depreciation and amortization expense of approximately $44 million, and capital expenditures of approximately $45 million. Fiscal 2026 guidance is based on foreign currency exchange rates as of April 30, 2026 and assumes continued economic growth. Fiscal 2026 guidance does not include any earnings impact from the PSS transaction.

A webcast regarding Brady’s fiscal 2026 third quarter financial results will be available at www.bradycorp.com/investors beginning at 9:30 a.m. central time today.

Brady Corporation is an international manufacturer and marketer of complete solutions that identify and protect people, products and places. Brady’s products help customers increase safety, security, productivity and performance and include high-performance labels, signs, safety devices, printing systems and software. Founded in 1914, the Company has a diverse customer base in electronics, telecommunications, manufacturing, electrical, construction, medical, aerospace and a variety of other industries. Brady is headquartered in Milwaukee, Wisconsin and as of July 31, 2025, employed approximately 6,400 people in its worldwide businesses. Brady’s fiscal 2025 sales were approximately $1.51 billion. Brady stock trades on the New York Stock Exchange under the symbol BRC. More information is available on the Internet at www.bradyid.com.

* Adjusted Income Before Income Taxes, Adjusted Net Income, and Adjusted Diluted EPS are non-GAAP measures. See appendix for more information on these measures, including reconciliations to the most directly comparable GAAP measures.

In this news release, statements that are not reported financial results or other historic information are “forward-looking statements.” These forward-looking statements relate to, among other things, the Company's future financial position, business strategy, targets, projected sales, costs, earnings, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations.

The use of words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “project,” “plan” or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements by their nature address matters that are, to different degrees, uncertain and are subject to risks, assumptions, and other factors, some of which are beyond Brady’s control, that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For Brady, uncertainties arise from: increased cost of materials, labor, material shortages and supply chain disruptions, including as a result of tariffs or other impacts of the global trade environment; decreased demand for our products; our ability to compete effectively or to successfully execute our strategy; our ability to develop technologically advanced products that meet customer demands; Brady’s ability to identify, integrate and grow acquired companies; difficulties in protecting our websites, networks, and systems against security breaches and difficulties in preventing phishing attacks, social engineering or malicious break-ins; risks associated with the loss of key employees; litigation, including product liability claims; global climate change and environmental regulations; foreign currency fluctuations; changes in tax legislation and tax rates; potential write-offs of goodwill and other intangible assets; differing interests of voting and non-voting shareholders and changes in the regulatory and business environment around dual-class voting structures; the possibility that events, changes or other circumstances could result in termination of the agreement to acquire the PSS business; our ability to complete the pending acquisition of the PSS business on the anticipated timeline or at all, including risks related to the timing, receipt and terms of required governmental and regulatory approvals and the satisfaction or waiver of other closing conditions; the potential effects of the pending acquisition and related integration planning on Brady’s and the PSS business’s relationships with customers, suppliers and other business partners, ability to retain and hire key personnel, operating results and businesses generally; our ability to realize the anticipated strategic and financial benefits of the pending acquisition of the PSS business, including expected synergies, within the anticipated timeframe, or at all; numerous other matters of national, regional and global scale, including major public health crises and government responses thereto and those of a political, economic, business, competitive, and regulatory nature contained from time to time in Brady’s U.S. Securities and Exchange Commission filings, including, but not limited to, those factors listed in the “Risk Factors” section within Item 1A of Part I of Brady’s Form 10-K for the year ended July 31, 2025.

These uncertainties may cause Brady's actual future results to be materially different than those expressed in its forward-looking statements. Brady does not undertake to update its forward-looking statements except as required by law.

 BRADY CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited; Dollars in thousands, except per share data)
         Three months ended April 30, Nine months ended April 30,  2026   2025   2026   2025 Net sales$435,237  $382,590  $1,224,661  $1,116,330 Cost of goods sold 209,768   187,531   595,966   555,739 Gross margin 225,469   195,059   628,695   560,591 Operating expenses:       Research and development 23,531   19,191   71,132   56,835 Selling, general and administrative 128,732   108,678   354,195   326,410 Total operating expenses 152,263   127,869   425,327   383,245         Operating income 73,206   67,190   203,368   177,346         Other income (expense):       Investment and other income (expense) 1,431   (509)  3,948   2,850 Interest expense (1,269)  (936)  (3,467)  (3,604)        Income before income taxes 73,368   65,745   203,849   176,592         Income tax expense 15,568   13,482   44,062   37,212         Net income$57,800  $52,263  $159,787  $139,380         Net income per Class A Nonvoting Common Share:       Basic$1.22  $1.10  $3.38  $2.92 Diluted$1.21  $1.09  $3.35  $2.89         Net income per Class B Voting Common Share:       Basic$1.22  $1.10  $3.36  $2.90 Diluted$1.21  $1.09  $3.33  $2.88         Weighted average common shares outstanding:       Basic 47,357   47,644   47,313   47,743 Diluted 47,814   48,066   47,761   48,196      BRADY CORPORATION AND SUBSIDIARIES   CONSOLIDATED BALANCE SHEETS   (Dollars in thousands)        April 30, 2026 July 31, 2025 (Unaudited)  ASSETS   Current assets:   Cash and cash equivalents$175,491  $174,349 Accounts receivable, net of allowance for credit losses of $7,274 and $7,876 respectively 266,354   231,944 Inventories 220,252   200,881 Prepaid expenses and other current assets 16,832   14,661 Total current assets 678,929   621,835 Property, plant and equipment—net 243,720   225,572 Goodwill 689,415   676,945 Other intangible assets 103,425   105,374 Deferred income taxes 18,503   20,862 Operating lease assets 61,154   58,422 Other assets 36,805   25,243 Total$1,831,951  $1,734,253 LIABILITIES AND STOCKHOLDERS’ EQUITY   Current liabilities:   Accounts payable$108,454  $105,028 Accrued compensation and benefits 92,253   92,657 Taxes, other than income taxes 22,308   21,537 Accrued income taxes 4,787   5,547 Current operating lease liabilities 16,382   15,234 Other current liabilities 93,620   90,329 Total current liabilities 337,804   330,332 Long-term debt 26,857   99,766 Long-term operating lease liabilities 45,270   43,565 Other liabilities 78,035   68,379 Total liabilities 487,966   542,042 Stockholders’ equity:   Common stock:   Class A nonvoting common stock—Issued 51,261,487 shares, and outstanding 43,650,910 and 43,530,012 shares, respectively 513   513 Class B voting common stock—Issued and outstanding, 3,538,628 shares 35   35 Additional paid-in capital 363,578   359,269 Retained earnings 1,442,868   1,317,739 Treasury stock—7,610,577 and 7,731,475 shares, respectively, of Class A nonvoting common stock, at cost (393,992)  (393,186)Accumulated other comprehensive loss (69,017)  (92,159)Total stockholders’ equity 1,343,985   1,192,211 Total$1,831,951  $1,734,253      BRADY CORPORATION AND SUBSIDIARIES   CONSOLIDATED STATEMENTS OF CASH FLOWS   (Unaudited; Dollars in thousands)    Nine months ended April 30,  2026   2025 Operating activities:   Net income$159,787  $139,380 Adjustments to reconcile net income to net cash provided by operating activities:   Depreciation and amortization 33,549   30,279 Stock-based compensation expense 11,605   9,762 Deferred income taxes 9,506   (6,038)Other (4,857)  (181)Changes in operating assets and liabilities:   Accounts receivable (28,102)  (6,869)Inventories (12,970)  (8,209)Prepaid expenses and other assets (1,098)  (3,754)Accounts payable and accrued liabilities (1,638)  (26,415)Income taxes (883)  (5,081)   Net cash provided by operating activities 164,899   122,874     Investing activities:   Purchases of property, plant and equipment (32,994)  (18,685)Acquisition of businesses, net of cash acquired (17,416)  (147,248)Other 6,848   854    Net cash used in investing activities (43,562)  (165,079)    Financing activities:   Payment of dividends (34,658)  (34,237)Proceeds from exercise of stock options 9,168   5,759 Payments for employee taxes withheld from stock-based awards (3,406)  (2,518)Purchase of treasury stock (14,130)  (33,155)Proceeds from borrowing on credit agreement 73,500   206,249 Repayment of borrowing on credit agreement (146,409)  (194,365)Other (9,534)  190    Net cash used in financing activities (125,469)  (52,077)    Effect of exchange rate changes on cash and cash equivalents 5,274   (3,682)    Net increase (decrease) in cash and cash equivalents 1,142   (97,964)Cash and cash equivalents, beginning of period 174,349   250,118     Cash and cash equivalents, end of period$175,491  $152,154      BRADY CORPORATION AND SUBSIDIARIES
SEGMENT INFORMATION
(Unaudited; Dollars in thousands)
         Three months ended April 30, Nine months ended April 30,  2026   2025   2026   2025 NET SALES       Americas & Asia$290,055  $253,652  $810,552  $732,926 Europe & Australia 145,182   128,938   414,109   383,404 Total$435,237  $382,590  $1,224,661  $1,116,330         SALES INFORMATION       Americas & Asia       Organic 10.1%  5.4%  6.0%  5.0%Acquisitions 3.1%  8.6%  3.9%  7.9%Currency 1.2%  (1.1)%  0.7%  (1.0)%Divestiture —%  —%  —%  (0.5)%Total 14.4%  12.9%  10.6%  11.4%Europe & Australia       Organic 4.5%  (5.4)%  0.9%  (1.9)%Acquisitions —%  14.2%  —%  14.8%Currency 8.1%  (0.1)%  7.1%  (0.1)%Total 12.6%  8.7%  8.0%  12.8%Total Company       Organic 8.2%  1.6%  4.3%  2.6%Acquisitions 2.1%  10.5%  2.5%  10.2%Currency 3.5%  (0.7)%  2.9%  (0.5)%Divestiture —%  —%  —%  (0.4)%Total 13.8%  11.4%  9.7%  11.9%        SEGMENT PROFIT       Americas & Asia$68,730  $57,164  $182,344  $158,148 Europe & Australia 21,470   17,478   55,624   41,872 Total segment profit$90,200  $74,642  $237,968  $200,020 SEGMENT PROFIT AS A PERCENT OF NET SALES       Americas & Asia 23.7%  22.5%  22.5%  21.6%Europe & Australia 14.8%  13.6%  13.4%  10.9%Total 20.7%  19.5%  19.4%  17.9%                 Three months ended April 30, Nine months ended April 30,  2026   2025   2026   2025 Total segment profit$90,200  $74,642  $237,968  $200,020 Unallocated amounts:       Administrative costs (16,994)  (7,452)  (34,600)  (22,674)Investment and other income (expense) 1,431   (509)  3,948   2,850 Interest expense (1,269)  (936)  (3,467)  (3,604)Income before income taxes$73,368  $65,745  $203,849  $176,592          GAAP to NON-GAAP MEASURES
(Unaudited; Dollars in Thousands, Except Per Share Amounts)          In accordance with the U.S. Securities and Exchange Commission’s Regulation G, the following provides definitions of the non-GAAP measures used in the earnings release and the reconciliation to the most closely related GAAP measure.          Adjusted Income Before Income Taxes:    Brady is presenting the non-GAAP measure, “Adjusted Income Before Income Taxes.” This is not a calculation based upon GAAP. The amounts included in this non-GAAP measure are derived from amounts included in the Consolidated Financial Statements and supporting footnote disclosures. We do not view these items to be part of our ongoing results. We believe this profit measure provides an important perspective of underlying business trends and results and provides a more comparable measure from year to year. The table below provides a reconciliation of the GAAP measure of Income before income taxes to the non-GAAP measure of Adjusted Income Before Income Taxes:             Three months ended April 30, Nine months ended April 30,    2026  2025  2026  2025Income before income taxes$73,368 $65,745 $203,849 $176,592 Amortization expense  5,255  4,754  15,768  14,138 Non-recurring acquisition-related costs and other related expenses  13,506  -  13,506  5,059 Facility closure and other reorganization costs  -  3,930  -  9,584Adjusted Income Before Income Taxes (non-GAAP measure)$92,129 $74,429 $233,123 $205,373                    Adjusted Income Tax Expense:    Brady is presenting the non-GAAP measure, “Adjusted Income Tax Expense.” This is not a calculation based upon GAAP. The amounts included in this non-GAAP measure are derived from amounts included in the Consolidated Financial Statements and supporting footnote disclosures. We do not view these items to be part of our ongoing results. We believe this measure provides an important perspective of underlying business trends and results and provides a more comparable measure from year to year. The table below provides a reconciliation of the GAAP measure of Income tax expense to the non-GAAP measure of Adjusted Income Tax Expense:             Three months ended April 30, Nine months ended April 30,    2026  2025  2026  2025Income tax expense (GAAP measure)$15,568 $13,482 $44,062 $37,212 Amortization expense  1,267  1,144  3,803  3,402 Non-recurring acquisition-related costs and other related expenses  3,376  -  3,376  1,265 Facility closure and other reorganization costs  -  983  -  2,396Adjusted Income Tax Expense (non-GAAP measure)$20,211 $15,609 $51,241 $44,275                    Adjusted Net Income:    Brady is presenting the non-GAAP measure, “Adjusted Net Income.” This is not a calculation based upon GAAP. The amounts included in this non-GAAP measure are derived from amounts included in the Consolidated Financial Statements and supporting footnote disclosures. We do not view these items to be part of our ongoing results. We believe this measure provides an important perspective of underlying business trends and results and provides a more comparable measure from year to year. The table below provides a reconciliation of the GAAP measure of Net income to the non-GAAP measure of Adjusted Net Income:             Three months ended April 30, Nine months ended April 30,    2026  2025  2026  2025Net income (GAAP measure)$57,800 $52,263 $159,787 $139,380 Amortization expense  3,988  3,610  11,965  10,736 Non-recurring acquisition-related costs and other related expenses  10,130  -  10,130  3,794 Facility closure and other reorganization costs  -  2,947  -  7,188Adjusted Net Income (non-GAAP measure)$71,918 $58,820 $181,882 $161,098                    Adjusted Diluted EPS:    Brady is presenting the non-GAAP measure, “Adjusted Diluted EPS.” This is not a calculation based upon GAAP. The amounts included in this non-GAAP measure are derived from amounts included in the Consolidated Financial Statements. We do not view these items to be part of our ongoing results. We believe this measure provides an important perspective of underlying business trends and results and provides a more comparable measure from year to year. The table below provides a reconciliation of the GAAP measure of Net income per Class A Nonvoting Common Share to the non-GAAP measure of Adjusted Diluted EPS (Note that certain amounts will not foot due to rounding):             Three months ended April 30, Nine months ended April 30,    2026  2025  2026  2025Net income per Class A Nonvoting Common Share (GAAP measure)$1.21 $1.09 $3.35 $2.89 Amortization expense  0.08  0.08  0.25  0.22 Non-recurring acquisition-related costs and other related expenses  0.21  -  0.21  0.08 Facility closure and other reorganization costs  -  0.06  -  0.15Adjusted Diluted EPS (non-GAAP measure)$1.50 $1.22 $3.81 $3.34                    Adjusted Dilued EPS Guidance:     Fiscal 2026 Expectations       Low HighEarnings per diluted Class A Common Share (GAAP measure)     $4.66 $4.76 Amortization expense      0.33  0.33 Non-recurring acquisition-related costs and other related expenses      0.21  0.21Adjusted Diluted EPS (non-GAAP measure)     $5.20 $5.30 For More Information:
Investor contact: Ann Thornton 414-438-6887
Media contact: Kate Venne 414-358-5176

Brady NYSE: BRC reported what Chief Executive Officer Russell Shaller called a “fantastic quarter,” as the identification and safety products company posted record adjusted earnings per share and broad-based organic sales growth in its fiscal 2026 third quarter.

The company reported adjusted diluted earnings per share of $1.50, up 23% from $1.22 in the same quarter last year and a new quarterly record. GAAP diluted earnings per share rose to $1.21 from $1.09. Net income increased 10.6% to $57.8 million, while adjusted net income rose 22.3% to $71.9 million.

Organic sales grew 8.2% in the quarter, with total sales growth of 13.8% after including contributions from acquisitions and foreign currency translation. Chief Financial Officer Ann Thornton said the results reflected “strong organic sales growth, improved gross profit margin, efficiencies throughout SG&A, and growth in operating income throughout our global businesses.”

Get Brady alerts:

Sales Growth Led by Both Regions Brady said both of its operating regions contributed to the quarter’s organic growth. The Americas and Asia region grew organic sales 10.1%, while Europe and Australia grew 4.5% organically.

In Americas and Asia, sales reached a record $290.1 million, up 14.4% on a reported basis. Shaller said Brady grew sales in all key product lines in the region, with particular strength in wire identification. Wire ID represents 20% of revenue in Americas and Asia, and sales in that product line increased 19% during the quarter.

Shaller said data centers are making a “meaningful impact” on growth in wire identification. He also cited strong sales of portable, benchtop and automated printer units, which supported growth across wire identification, product identification and safety and facility identification.

In Europe and Australia, total sales rose 12.6% to $145.2 million, aided by an 8.1% benefit from foreign currency translation. Shaller said the region returned to growth despite a weak manufacturing environment in Europe and conflict in the Middle East. Wire ID represents 13% of sales in Europe and Australia and grew 13% in the quarter.

Margins and Cash Flow Improve Gross profit margin improved to 51.8% from 51.0% in the prior-year quarter. Thornton said the improvement reflected cost reduction actions taken last year, including the closure of manufacturing facilities in Beijing, China, and Buffalo, New York, as well as sales growth led by highly engineered products.

SG&A expense was $128.7 million, compared with $108.7 million a year earlier. As a percentage of sales, SG&A increased to 29.6% from 28.4%. Excluding amortization, acquisition-related expenses and certain prior-year reorganization costs, however, SG&A declined to 25.3% of sales from 26.5%.

Brady continued to increase research and development spending. R&D expense was $23.5 million, or 5.4% of sales, compared with $19.2 million, or 5.0% of sales, in the prior-year quarter. Thornton said printer unit sales increased nearly 8% year over year, adding that consumable revenue is expected to follow printer placements.

Operating cash flow increased 30.7% to $78.2 million, while free cash flow rose 20.8% to $67.2 million. Year to date, operating cash flow was up nearly 35%. Brady ended the quarter with a net cash position of $148.6 million, which Thornton said was more than triple the company’s net cash position a year earlier.

Guidance Raised for Fiscal 2026 Brady raised its full-year adjusted EPS guidance to a range of $5.20 to $5.30, up from its previous range of $4.95 to $5.15. The company said the new adjusted EPS outlook implies growth of 13% to 15.2% compared with fiscal 2025.

The company also updated its GAAP EPS guidance to a range of $4.66 to $4.76, compared with the prior range of $4.62 to $4.82. Brady continues to expect organic sales growth in the mid-single-digit percentage range for the fiscal year ending July 31, 2026.

Other guidance assumptions include depreciation and amortization expense of approximately $44 million, capital expenditures of approximately $45 million and a full-year income tax rate of about 21%. Thornton said potential risks include a stronger U.S. dollar, inflationary pressures the company cannot offset quickly enough and a broader slowdown in economic activity.

Honeywell PSS Acquisition in Focus Brady also discussed its previously announced agreement to acquire Honeywell’s Productivity Solutions and Services, or PSS, business. Shaller said the transaction would more than double the markets Brady can serve and add enterprise-level workforce productivity as a “critical third pillar” to the company’s customer offering.

Shaller said the combination would bring together Brady’s durable labels, printers, software and specialty adhesive materials with PSS’s mobility and scanning solutions. He said Brady intends to preserve PSS’s customer and channel partner relationships and continue investing in R&D and software offerings, including operational intelligence, voice and SwiftDecoder.

Brady said PSS sales declined by just under 2% in calendar 2025 compared with calendar 2024, then grew nearly 5% in the first quarter of calendar 2026. Shaller said Brady expects the acquired business to add approximately $0.80 of adjusted EPS accretion in the first year after closing, excluding synergies. He said the company’s best estimate for closing remains Aug. 1, pending regulatory filings and other external factors.

Thornton said Brady plans to finance the acquisition with $500 million of Term Loan A bank debt and $800 million of private placement debt, with an expected interest rate below 6%. She said the company expects net leverage of approximately 2.0 to 2.5 times at closing and expects to delever below 2 times within two years.

Executives Address Data Centers, New Printer and Board Resignations During the question-and-answer session, Shaller said data center-related demand remains a tailwind, particularly for wire identification. He said Brady is not seeing acceleration or deceleration from current trends, but views the pace of data center construction as supportive of multi-year demand rather than a short-term surge.

Asked about the i4311 portable 4-inch printer launched in February, Shaller said it is performing about 50% above the company’s normal expectations for a printer launch. He described the product as “new to the world” and said it allows users to print larger-format thermal transfer labels without returning to a printer station.

Shaller also addressed recent board resignations, saying the optics were “awful” but attributing the departures to the significantly increased time commitment required by the Honeywell transaction. He said all board members present for the acquisition vote supported the deal and that there was “no dissent.”

“We reported an excellent quarter,” Shaller said in closing, adding that Brady’s investments in R&D are paying off and that the company finished the quarter with momentum.

About Brady NYSE: BRCBrady Corporation is a global provider of identification and safety solutions, specializing in the design, manufacture and sale of products that help businesses improve safety, security and efficiency. The company offers an array of durable labels, signs, safety devices, printing systems and software platforms tailored to a wide range of industrial and commercial environments.

Founded in 1914 by William H. Brady, Brady Corporation has grown from a regional marker manufacturer into a diversified global enterprise.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Brady Right Now?Before you consider Brady, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brady wasn't on the list.

While Brady currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Brady Corporation (BRC) Q3 2026 Earnings Call Transcript

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the “Greed” zone on Monday.

U.S. stocks settled mixed on Monday, with the S&P 500 and Nasdaq Composite falling during the session amid declines in tech stocks.

President Donald Trump struck an uncompromising tone on Iran, posting that the conflict would end only when Tehran issued "Documents of Surrender" and "admit their defeat to the great power and force of the magnificent U.S.A."

In earnings, Brady Corp. (NYSE:BRC) reported upbeat first-quarter earnings on Monday.

On the economic data front, the NAHB/Wells Fargo Housing Market Index climbed to 37 in May from 34 in April. The New York Fed’s Services Business Activity Index rose 8.2 points to a reading of -5.8 in May.

Most sectors on the S&P 500 closed on a positive note, with energy, financial and consumer staples stocks recording the biggest gains on Monday. However, information technology and industrials stocks closed the session lower.

The Dow Jones closed higher by around 160 points to 49,686.12 on Monday. The S&P 500 fell 0.07% to 7,403.05, while the Nasdaq Composite dipped 0.51% at 26,090.73 during Monday's session.

What Is CNN Business Fear & Greed Index?At a current reading of 61.8, the index remained in the “Greed” zone on Monday, versus a prior reading of 63.

The Fear & Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

May 19, 2026 18:10 ET  | Source: Brady Corporation

MILWAUKEE, May 19, 2026 (GLOBE NEWSWIRE) -- On May 19, 2026, Brady Corporation’s (NYSE: BRC) Board of Directors declared a dividend to shareholders of the company’s Class A Common Stock of $0.245 per share, payable on July 31, 2026, to shareholders of record at the close of business on July 10, 2026.

Brady Corporation is an international manufacturer and marketer of complete solutions that identify and protect people, products and places. Brady’s products help customers increase safety, security, productivity and performance and include high-performance labels, signs, safety devices, printing systems and software. Founded in 1914, the Company has a diverse customer base in electronics, telecommunications, manufacturing, electrical, construction, medical, aerospace and a variety of other industries. Brady is headquartered in Milwaukee, Wisconsin and as of July 31, 2025, employed approximately 6,400 people in its worldwide businesses. Brady’s fiscal 2025 sales were approximately $1.51 billion. Brady stock trades on the New York Stock Exchange under the symbol BRC. More information is available on the Internet at www.bradyid.com.

For More Information Contact:
Investor Contact: Ann Thornton (414) 438-6887
Media Contact: Kate Venne (414) 438-5176

-

Sourced from organic Vietnamese coconuts, Good Nut delivers clean, refreshing hydration in three innovative flavors, including the first certified organic chocolate coconut water on the market

PHILADELPHIA--(BUSINESS WIRE)--Seven-time World Champion, entrepreneur, and philanthropist Tom Brady is bringing his relentless pursuit of peak performance to the beverage aisle. As the latest expansion of his partnership with Gopuff, the leader in instant commerce, Brady today announced the launch of Good Nut, a premium line of organic coconut water designed for those who refuse to compromise on quality or taste, available exclusively on Gopuff.

Gopuff and Tom Brady launch Good Nut, a premium line of organic coconut water designed for those who refuse to compromise on quality or taste. Now available exclusively on Gopuff.

Share “Hydration has always been a big part of my routine, and while coconut water has been a staple for me, I knew we could take it to a completely different level by teaming up with Gopuff,” said Tom Brady. “With Good Nut, we focused on keeping the ingredients simple and clean, making sure it’s exactly what I’d want in my own fridge.”

As consumers continue to seek less processed, lower-sugar beverages, the global market for coconut water is expected to reach $11 billion by 2030. This demand is also evident with Gopuff customers as coconut water sales have surged 115% year-over-year on the platform.

Capitalizing on this shift, Good Nut offers a premium alternative to over-processed sports drinks. Sourced from organic Vietnamese coconuts and with no added sugars, Good Nut delivers a clean, refreshing hydration experience in a sleek 11.8 oz can. True to Brady’s disciplined approach to nutrition, the entire line contains no added sweeteners and nothing artificial. Good Nut is available in three delicious flavors, including:

Original Coconut Water: Made from handpicked Vietnamese coconuts, refined for flavor, texture, and refreshment down to the last sip. It’s the perfect, clean coconut water. Chocolate Coconut Water: Move over, chocolate milk. Made with only three, simple ingredients, and no added sugars, Good Nut Chocolate Coconut Water is rich and creamy, even without the dairy. It’s the first and only certified organic chocolate coconut water on the market. Sparkling Coconut Water: Brighter, bubblier and refreshing in a way plain water never could be. “Good Nut started with Tom telling us about how much he loves drinking chocolate coconut water,” said Tyler Stewart, Head of Marketing at Gopuff. “We quickly realized there was an opportunity to shake up the category with a product that tastes incredible, uses great ingredients, and has a bold brand that gets people talking. Blending premium products with brands that are playful, unexpected, and don’t take themselves too seriously has become a huge part of how we build together with Tom. Whether it’s GOAT Gummies, our lobbying campaign with Super Monday Off, or now Good Nut, we’re always trying to give our customers and fans more of what they want, and of course entertain them a little along the way.”

To kick off the launch, Brady leans into Good Nut’s unconventional name with a new brand video. Throughout the video, Brady delivers a polished pitch highlighting the quality and benefits of the product, yet he consistently stops short of naming it. The punchline, of course, is the name he refuses to say: Good Nut. Watch it here!

Whether recovering from a workout or looking for a clean afternoon pick-me-up, Gopuff ensures that fans and health-conscious consumers can get Good Nut’s elite-level hydration delivered in as fast as 15 minutes. Beginning today, Good Nut is available exclusively on Gopuff for $3.29 per can, with discounted pricing of $2.96 per can available to FAM members.

Gopuff was built to bring the world’s best products to your door in minutes, but it has evolved into a platform where some of those products are born. The company has established itself as the go-to launchpad and growth engine for emerging talent-led brands, including Tom Brady’s GOAT Gummies, Selena Gomez’s co-branded Serendipity ice cream bars, Giannis Antetokounmpo's FR34K Gummies, a limited-edition Halloween chocolate bar with Alix Earle, and more. With nationwide infrastructure, control over its inventory, and a model built for speed, Gopuff connects fans with their favorite brands in minutes.

About Gopuff

Gopuff, the leader in instant commerce, offers more than 5,000 products delivered in as fast as 15 minutes. Founded in 2013 by Yakir Gola and Rafael Ilishayev, the company operates its own micro-fulfillment centers, leveraging proprietary technology and a hyper-local logistics network to offer speed, reliability, and affordability to millions of customers across the U.S. and U.K.

To learn more, visit www.gopuff.com or follow Gopuff on Facebook, X or Instagram. Download the Gopuff app on iOS and Android.

More News From Gopuff

Back to Newsroom

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Considering buying BRC stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of The Ensign Group, Inc. (“Ensign” or the “Company”) (NASDAQ: ENSG) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON THE ENSIGN GROUP, INC. (ENSG), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On June 8, 2026, investment media group Hunterbrook Media published a report entitled “Ensign: The Nursing Home Empire Built of Fatal Neglect.” The report alleges that “Ensign’s business model relies on delivering inadequate care to patients while gaming data.” The report also alleges that “former employees in different states described systematic misrepresentations.”

On this news, Ensign’s stock price fell as much as 11% during intraday trading on June 8, 2026, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Ensign securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com.
Email us at: [email protected] us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From The Law Offices of Frank R. Cruz

Boston, Massachusetts--(Newsfile Corp. - June 9, 2026) - Block & Leviton is investigating The Ensign Group, Inc. (NASDAQ: ENSG) for potential securities law violations. Investors who have lost money in their The Ensign Group, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/ensg.

What is this all about?

The Ensign Group fell more than 5% in intraday trading on June 8, 2026 after Hunterbrook Media published a report alleging that Ensign's growth and profitability were driven by chronic understaffing at its nursing facilities, resulting in inadequate patient care, violations of staffing requirements, misleading quality metrics, and substantial related-party payments. The report further alleged that former employees described document falsification, improper billing practices, and efforts to manipulate performance data while the Company touted industry-leading clinical outcomes and quality ratings.

Who is eligible?

Anyone who purchased The Ensign Group, Inc. common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.

What is Block & Leviton doing?

Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

What should you do next?

If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (888) 256-2510.

Whistleblower?

If you have non-public information about The Ensign Group, Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510.

Why should you contact Block & Leviton?

Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email [email protected] with any questions.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (888) 256-2510
Email: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300734

Source: Block & Leviton LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

-

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of The Ensign Group, Inc. (“Ensign” or the “Company”) (NASDAQ: ENSG) investors concerning the Company’s possible violations of the federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON ENSIGN GROUP, INC. (ENSG), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?

On June 8, 2026, investment media group Hunterbrook Media published a report entitled “Ensign: The Nursing Home Empire Built of Fatal Neglect.” The report alleges that “Ensign’s business model relies on delivering inadequate care to patients while gaming data.” The report also alleges that “former employees in different states described systematic misrepresentations.”

On this news, Ensign’s stock price fell $13.88, or 8.2%, to close at $156.42 per share on June 8, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.

Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice

Persons with non-public information regarding Ensign should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP

GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm’s recent successes, GPWR was named one of Law360’s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From Glancy Prongay Wolke & Rotter LLP

Back to Newsroom

The Ensign Group reported 85% of facilities at 4- or 5-star quality ratings on its Q1 2026 earnings call. A short-seller report alleges those ratings were gamed -- and the stock dropped sharply.

, /PRNewswire/ -- Investors in The Ensign Group (NASDAQ: ENSG) lost significant value when shares dropped sharply after a Hunterbrook short-seller report on June 8, 2026, alleged systemic quality-measure gaming at the skilled nursing facility operator. Shareholders who lost money on ENSG are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

On the Company's Q1 2026 earnings call on May 1, 2026, CEO Barry Port told investors: "85% of all of our operations are at 4- or 5-star quality measures." He also stated that same-store and transitioning occupancy had reached "new record highs during the quarter of 84.3% and 85.1%, respectively." On June 8, 2026, the Hunterbrook report alleged that those quality ratings had been inflated through systematic manipulation of CMS star-rating data. ENSG shares fell sharply on the news.

CMS star ratings are a primary driver of reimbursement rates and facility valuations in the skilled nursing industry. The Company presented these metrics as evidence of operational excellence and used them as the basis for raising forward guidance during the same earnings call. The Hunterbrook report's allegations that these ratings did not reflect actual care quality called those representations into question.

If you purchased The Ensign Group shares and suffered a loss, click here to discuss your legal rights. You may also reach Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

SueWallSt -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the ENSG Investigation

Q: Who is eligible to participate in the ENSG investigation?A: Investors who purchased ENSG stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether The Ensign Group made materially false or misleading statements regarding quality-measure performance, occupancy figures, and staffing metrics. When a short-seller report challenged those representations on June 8, 2026, the stock price declined sharply.

Q: How much did ENSG stock drop?A: Shares fell sharply after Hunterbrook published a report alleging systemic quality-measure gaming, neglect, and improper billing practices at The Ensign Group's facilities.

Q: What do ENSG investors need to do right now?A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible to participate in the investigation.

Q: What if I already sold my ENSG shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ENSG and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

SOURCE SueWallSt.com

SAN DIEGO, June 10, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether The Ensign Group, Inc. (NASDAQ: ENSG) or certain of its executive officers violated state or federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

What if I purchased Ensign securities?

If you purchased Ensign securities and suffered losses on your investment, join our investigation now: Click Here to Join the Investigation.

Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.

There is no cost or obligation to you.

Background of the Investigation

On June 8, 2026, Hunterbrook Media published a report concerning The Ensign Group, Inc. The report alleged, among other things, that Ensign’s growth and profitability were driven by chronic understaffing at its nursing facilities, resulting in inadequate patient care, violations of staffing requirements, misleading quality metrics, and substantial related-party payments.

Hunterbrook further alleged that Ensign’s facilities reported superior quality metrics while allegedly performing worse on independently verifiable measures. The report also alleged that former employees described document falsification, improper billing practices, efforts to manipulate performance data, and other practices that allegedly conflicted with the Company’s public statements regarding its clinical outcomes and quality ratings.

Following publication of the Hunterbrook report, Ensign’s stock price declined in intraday trading.

In light of these allegations, Johnson Fistel is investigating whether Ensign complied with federal laws. If you suffered losses, or are a long-term holder of Ensign stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Top Law Firm – Securities Fraud & Investor Rights

Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder litigation involving securities fraud, breaches of fiduciary duties, and other violations of state and federal law.

Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.

Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. This press release may be considered a promotional communication. The attorney responsible for this communication is Frank J. Johnson.

Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations
(619) 814-4471
[email protected]

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Ensign Group, Inc. (“Ensign” or “the Company”) (NASDAQ: ENSG) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ensign is the subject of a report published by Hunterbrook Media that alleges its profitability depends on understaffing at nursing facilities, which in turn resulted in poor patient care, violations of staffing requirements, and other negative impacts. The report also claims that former employees say the Company manipulated performance data.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610103274/en/

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

So What: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On June 8, 2026, Investing.com published an article entitled "Ensign Group stock tumbles after short seller report." The article stated that Ensign shares fell after "short seller Hunterbrook released a report alleging the nursing home operator's business model relies on inadequate patient care and gaming quality metrics." Further, the article stated that Hunterbrook "published findings from a five-month investigation claiming the company's profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates. The report alleges patients have suffered and died as a result."

On this news, Ensign Group shares fell sharply in intraday trading on June 8, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Boston, Massachusetts--(Newsfile Corp. - June 11, 2026) - Block & Leviton is investigating The Ensign Group, Inc. (Nasdaq: ENSG) for potential securities law violations. Investors who have lost money in their The Ensign Group, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/ensg.

What is this all about?

The Ensign Group fell more than 5% in intraday trading on June 8, 2026 after Hunterbrook Media published a report alleging that Ensign's growth and profitability were driven by chronic understaffing at its nursing facilities, resulting in inadequate patient care, violations of staffing requirements, misleading quality metrics, and substantial related-party payments. The report further alleged that former employees described document falsification, improper billing practices, and efforts to manipulate performance data while the Company touted industry-leading clinical outcomes and quality ratings.

Who is eligible?

Anyone who purchased The Ensign Group, Inc. common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.

What is Block & Leviton doing?

Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

What should you do next?

If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (888) 256-2510.

Whistleblower?

If you have non-public information about The Ensign Group, Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510.

Why should you contact Block & Leviton?

Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email [email protected] with any questions.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (888) 256-2510
Email: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301155

Source: Block & Leviton LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On June 8, 2026, Investing.com published an article entitled "Ensign Group stock tumbles after short seller report." The article stated that Ensign shares fell after "short seller Hunterbrook released a report alleging the nursing home operator’s business model relies on inadequate patient care and gaming quality metrics." Further, the article stated that Hunterbrook "published findings from a five-month investigation claiming the company’s profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates. The report alleges patients have suffered and died as a result."

On this news, Ensign Group shares fell sharply in intraday trading on June 8, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com